Log in to search using one of your social media accounts:

 

Glaukos touts IOP, medication use reductions in iStent trial
Glaukos (NYSE:GKOS) today released results from a study of its iStent trabecular micro-bypass stent exploring its use during cataract surgery in patients with severe open-angle glaucoma, touting significant reductions in intraocular pressure and medication use. The San Clemente, Calif.-based company’s iStent micro-bypass stents are made from non-ferromagnetic titanium and coated in heparin, is designed to be implanted into multiple trabecular meshwork through a single corneal entry point to reduce IOP. Results were published in the January issue of the Journal of Glaucoma. “Although the iStent&nb...
Source: Mass Device - February 8, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Optical/Ophthalmic Glaukos Source Type: news

Glaukos touts Ph2 glaucoma trial for drug-eluting implant
Glaukos (NYSE:GKOS) touted data today from a Phase II trial of its travoprost intraocular implant in a 12-month cohort of glaucoma patients. The company’s iDose device is placed during a micro-invasive procedure and filled with a special formulation of travoprost – a drug used to reduce intraocular pressure. The implant continuously delivers therapeutic levels of travoprost within the eye and when it’s depleted, the iDose is removed and replaced. Get the full story at our sister site, Drug Delivery Business News. The post Glaukos touts Ph2 glaucoma trial for drug-eluting implant appeared first on Mas...
Source: Mass Device - January 10, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat Glaukos Source Type: news

Glaukos wins FDA nod for IDE trial of iStent SA
Glaukos (NYSE:GKOS) said today it won FDA investigational device exemption to launch a pivotal study of its iStent SA trabecular micro-bypass system designed to treat glaucoma. The San Clemente, Calif.-based company’s iStent SA is designed to reduce intraocular pressure in psuedophakic, mild-to-moderate open-angle, pigmentary or psuedoexfoliative glaucoma patients, the company said. The system includes 2 micro-scale titanium stents in an auto-injection system which can be injected into trabecular meshwork locations through a single corneal entry point to restore physiological outflow of aqueous humor into the Sc...
Source: Mass Device - December 19, 2017 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Food & Drug Administration (FDA) Optical/Ophthalmic Regulatory/Compliance Glaukos Source Type: news

Glaukos touts iStent study with topical travoprost
Glaukos (NYSE:GKOS) touted data today from a 53-patient glaucoma study showing that its iStent device combined with topical travoprost reduced mean intraocular pressure by 35% after 18 months of follow-up. The company’s flagship device is designed to lessen IOP by restoring the natural outflow of aqueous humor through the conventional pathway in a patient’s eye. Get the full story at our sister site, Drug Delivery Business News. The post Glaukos touts iStent study with topical travoprost appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - June 21, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Stents Wall Street Beat Glaukos Source Type: news

Envisia reports positive interim results from Phase II trial of ENV515 in glaucoma
US-based clinical-stage biotechnology firm Envisia Therapeutics has reported positive interim results from the second cohort of the ENV515 (travoprost XR) Phase II trial to treat patients with glaucoma. (Source: Drug Development Technology)
Source: Drug Development Technology - February 6, 2017 Category: Pharmaceuticals Source Type: news

Glaukos touts IOP reduction in pseudophakic iStent study
Glaukos (NYSE:GKOS) today released data from a study of its iStent trabecular micro-bypass stent, touting reduced intraocular pressure when implanted in pseudophakic eyes with open-angle glaucoma. Data from the study was recently published in the Journal of Glaucoma, the Laguna Hills, Calif.-based company said. Glaukos’ iStent micro-bypass stents are made from non-ferromagnetic titanium and coated in heparin, is designed to be implanted into multiple trabecular meshwork through a single corneal entry point to reduce IOP, the company said. Pseudophakic eyes are eyes in which the natural lens has been removed...
Source: Mass Device - December 12, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Optical/Ophthalmic Glaukos Source Type: news

Izba (Travoprost Ophthalmic Solution) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 6, 2016 Category: Drugs & Pharmacology Source Type: news

Travatan (Travoprost) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 6, 2016 Category: Drugs & Pharmacology Source Type: news

Glaukos touts 3-year iStent data
Glaukos (NYSE:GKOS) today released 3-year results from a study of its iStent trabecular micro-bypass stents, touting a 43% reduction in mean intraocular pressure in glaucoma patients treated with the device. Results were published in the journal Ophthalmology and Therapy this month, the Laguna Hills, Calif.-based company said. Glaukos’ iStent micro-bypass stents are made from non-ferromagnetic titanium and coated in heparin, is designed to be implanted into multiple trabecular meshwork through a single corneal entry point to reduce IOP, the company said. Data in the prospective study came fro...
Source: Mass Device - September 23, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Optical/Ophthalmic Glaukos Source Type: news

Novartis taps Hospira-sale engineer exec Ball to revive slumping Alcon
Novartis (NYSE:NVS) is looking to revitalize its slumping Alcon eye care division by picking up medical vet Michael Ball, who recently organized Hospira’s $15 billion sale to Pfizer (NYSE:PFE). Ball will replace previous Alcon chief Jeff George, the company announced today. Novartis CEO Joe Jimenez is reportedly putting Ball in control of reviving Alcon. Alcon has been in a rut, with its glaucoma drug Travatan Z patent expiring last month, intraocular lens implant revenue slumping and an underperforming over-the-counter contact lens solution biz. “If you look at the mistakes that were made that have led to the ...
Source: Mass Device - January 27, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Optical/Ophthalmic Alcon Inc. Hospira Inc. Novartis AG Pfizer Inc. Source Type: news

Glaukos touts 3-year iStent study data
Glaukos (NYSE:GKOS) said today data from a 3-year study of its iStent Trabecular micro-bypass stent indicated that it, along with cataract surgery, lowered mean intraocular pressure 36% and reduced mean glaucoma medications by 86% 3 years post-surgery. The study reported a mean IP of 14.99 mmHg in 39 patients monitored after treatment for 3 years, compared to a mean preoperative IOP of 23.4 mmHG. The mean number of glaucoma medications used after 3 years dropped to 0.3, compared with a preoperative mean of 1.9 medications. No operative complications were reported, but 5 secondary surgeries, 2 postoperative ocular ocul...
Source: Mass Device - January 20, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Blog Glaukos Corp. Source Type: news

No quick fix seen for Novartis’s troubled Alcon unit
(Reuters) – Introduced a decade ago, glaucoma drug Travatan Z has been a powerful driver behind the success of Novartis (NYSE:NVS)’s Alcon eye care business, its second biggest division behind the main pharmaceuticals business. But the drug’s patent expiration last month, the latest in a wave of expiries that have left Alcon vulnerable to generics, brings into sharp focus the unit’s problems, for which analysts say there is no obvious quick fix. Having taken its first stake in Alcon eight years ago after it was floated by former-owner Nestle, Novartis now acknowledges the ophthalmic division has bec...
Source: Mass Device - January 12, 2016 Category: Medical Equipment Authors: MassDevice Tags: Business/Financial News Alcon Inc. Novartis AG Source Type: news

Glaukos submits IND for Travoprost eluting iDose
Glaukos (NYSE:GKOS) said it submitted an Investigational New Drug application to the FDA for its Travoprost intraocular implant delivered with the company’s iDose delivery system to reduce elevated intraocular pressure in patients with glaucoma. The Travoprost intraocular implant is injected through a clear corneal incision and secured in the anterior chamber, where the iDose system provides continuously elutes therapeutic levels of medication for an extended period of time, Glaukos said. “This IND submission represents a seminal milestone, which the Glaukos team achieved well ahead of our origin...
Source: Mass Device - November 20, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Food & Drug Administration (FDA) Optical/Ophthalmic Regulatory/Compliance Glaukos Corp. Source Type: news

Stents as Effective as Prostaglandin in GlaucomaStents as Effective as Prostaglandin in Glaucoma
Trabecular micro-bypass stents work as well as travoprost to reduce intraocular pressure in glaucoma, say researchers. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 4, 2015 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Novartis says Alcon's Travatan receives EU approval
ZURICH (Reuters) - Swiss pharmaceutical group Novartis said on Tuesday the European Commission had approved an additional treatment for its eyecare unit Alcon's Travatan treatment for glaucoma, a chronic, sight-threatening eye disease. (Source: Reuters: Health)
Source: Reuters: Health - December 23, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

Izba (Travoprost Ophthalmic Solution) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 29, 2014 Category: Drugs & Pharmacology Source Type: news

Travoprost in the Treatment of Ocular HypertensionTravoprost in the Treatment of Ocular Hypertension
What is the most effective dosing strategy of travoprost for the treatment of ocular hypertension? This new study compares daily vs alternate day use. Journal of Glaucoma (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 25, 2013 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news